The 755-subject trial showed median overall survival of 15,1 months for patients treated with cabazitaxel in combination with prednisone, a steroid, compared to 12,7 months for patients treated with a combination of the prostate cancer drug mitoxantrone and prednisone, the company said in a statement.
Men involved in the trial had metastatic hormone-refractory prostate cancer that had worsened despite treatment with docetaxel-based chemotherapy.
Sanofi said the cabazitaxel regimen “significantly reduced the risk of death by 30%.” The most serious side effects included low levels of white blood cells and infections. Nearly 5% of cabazitaxel patients died due to adverse events, compared to 2% in the mitoxantrone arm.
“These are the first data to show a statistical improvement in overall survival in patients with this difficult-to-treat and aggressive form of prostate cancer,” Dr. Oliver Sartor, the trial’s lead investigator and a cancer research professor at Tulane Medical School in New Orleans said in a statement.
Sanofi said the results will be presented on Friday at a San Francisco meeting sponsored by the American Society for Clinical Oncology.
Cabazitaxel recently received fast track designation from the US Food and Drug Administration — a process designed to expedite the review of drugs being developed for serious diseases with the potential to address an unmet medical need.
Just R20 for the first month. Support independent journalism by subscribing to our digital news package.